Use of differentiated pluripotent stem cells in replacement therapy for treating disease

Author:

Fox Ira J.1,Daley George Q.234,Goldman Steven A.56,Huard Johnny7,Kamp Timothy J.8,Trucco Massimo9

Affiliation:

1. Department of Surgery, Children’s Hospital of Pittsburgh and McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

2. Boston Children’s Hospital and Dana Farber Cancer Institute, Boston, MA, USA.

3. Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School Broad Institute, Cambridge, MA, USA.

4. Howard Hughes Medical Institute, Chevy Chase, MD, USA.

5. Center for Translational Neuromedicine, The University of Rochester Medical Center, Rochester, NY, USA.

6. Center for Basic and Translational Neuroscience, University of Copenhagen, Denmark.

7. Stem Cell Research Center, Department of Orthopaedic Surgery, University of Pittsburgh, School of Medicine, Pittsburgh, PA, USA.

8. Stem Cell and Regenerative Medicine Center, Cellular and Molecular Arrhythmia Research Program, Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA.

9. Division of Immunogenetics, Children’s Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, PA, USA.

Abstract

Challenges for stem cell–based therapies Patient-derived pluripotent stem cells (PSCs) hold promise in the treatment of injury and disease. An ever-increasing number of specific cell types can be generated from PSCs, but technical challenges remain in applying these cells in the clinic. Fox et al. review the challenges in attaining this goal. These include gene modification, cell rejection, and delivery and localization issues involved in transplantation of cells for the treatment of diabetes and disorders of the blood, liver, heart, and brain. Science , this issue 10.1126/science.1247391

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3